These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 14567959)

  • 1. Canavan disease: a monogenic trait with complex genomic interaction.
    Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
    Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease.
    Surendran S; Rady PL; Michals-Matalon K; Quast MJ; Rassin DK; Campbell GA; Ezell EL; Wei J; Tyring SK; Szucs S; Matalon R
    Brain Res Bull; 2003 Aug; 61(4):427-35. PubMed ID: 12909286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
    Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
    J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings.
    Matalon RM; Michals-Matalon K
    Front Biosci; 2000 Mar; 5():D307-11. PubMed ID: 10704428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
    Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
    Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
    J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
    Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
    Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of Canavan's disease: from human to mouse.
    Surendran S; Matalon KM; Tyring SK; Matalon R
    J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
    Becker I; Wang-Eckhardt L; Eckhardt M
    J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
    Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
    Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
    Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
    Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canavan disease: diagnosis and molecular analysis.
    Matalon R
    Genet Test; 1997; 1(1):21-5. PubMed ID: 10464621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
    Baslow MH; Guilfoyle DN
    Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canavan disease: clinical features and recent advances in research.
    Hoshino H; Kubota M
    Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canavan disease: from spongy degeneration to molecular analysis.
    Matalon R; Michals K; Kaul R
    J Pediatr; 1995 Oct; 127(4):511-7. PubMed ID: 7562269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canavan disease: a white matter disorder.
    Kumar S; Mattan NS; de Vellis J
    Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.